Rodrigo Ruiz-Soto

4PUBLICATIONS
45CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

|Sep 04, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.

Suzanne George, Jean-Yves Blay, Ping Chi

|Jul 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

Hans Gelderblom, Albiruni A Razak, Matthew H Taylor

|Aug 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

Sebastian Bauer, Robin L Jones, Jean-Yves Blay

Pageof 1

Frequent Collaborators

4 joint publications

Hans Gelderblom

3 joint publications

Sebastian Bauer

3 joint publications

Robin L Jones

3 joint publications

Jean-Yves Blay